The tablets would release the peptides in the colon, aimed at left-sided ulcerative colitis. Neither peptide is FDA-approved, and delivery tests so far used budesonide, not these peptides.
Recap by typeshit. Full story at Stock Titan.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
A repost points to a roundup of upcoming weight loss drugs, including ones that combine several hormone signals in a single treatment.
The endocrinologist explains that microdosing means taking far less than the doses recommended for treatment, and gives his view on the trend.
Loading…